​

TG Therapeutics Ownership | Who Owns TG Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

TG Therapeutics Ownership Summary

TG Therapeutics is owned by 22.55% institutional investors, 7.47% insiders, and 69.98% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.42% of TGTX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.41% of its assets in TG Therapeutics shares.

TGTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTG Therapeutics22.55%7.47%69.98%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de22.25M15.42%$739.24M
Vanguard group15.84M10.89%$472.22M
Blackrock11.39M7.79%$202.60M
State street8.65M5.99%$287.35M
Soleus capital management4.03M2.79%$133.85M
Geode capital management3.50M2.43%$116.29M
Clearbridge investments3.21M2.22%$106.67M
Goldman sachs group2.29M1.59%$76.00M
Congress asset management co /ma2.17M1.50%$72.02M
Bank of america corp /de/2.08M1.42%$37.04M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Act capital management249.03K6.50%$8.27M
M28 capital management lp88.35K5.46%$2.94M
Soleus capital management4.03M5.42%$133.85M
Ghost tree capital500.00K2.79%$8.89M
Opaleye management535.00K2.34%$17.77M
Knott david m jr90.00K1.78%$2.99M
Pandora wealth78.10K1.41%$2.33M
Penn capital management company541.96K1.40%$18.05M
Diadema partners lp206.93K1.17%$6.87M
683 capital management590.00K1.02%$19.60M

Top Buyers

HolderShares% AssetsChange
Jane street group2.04M0.01%1.07M
Vanguard fiduciary trust968.67K0.01%968.67K
Citadel advisors1.92M0.01%911.85K
Soleus capital management4.03M5.42%890.01K
Woodline partners lp715.50K0.09%715.50K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---1.73M
Vestal point capital, lp---1.05M
Invesco720.93K0.00%-888.88K
Driehaus capital management---807.83K
Eventide asset management---716.41K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust968.67K0.01%968.67K$32.18M
Woodline partners lp715.50K0.09%715.50K$23.77M
Norges bank401.50K0.00%401.50K$12.09M
Braidwell lp358.80K0.40%358.80K$11.92M
Renaissance340.90K0.02%340.90K$11.32M

Sold Out

HolderChange
Hfm investment advisors-1.00
Cedar mountain advisors-1.00
Global financial private client-2.00
Mendota financial group-4.00
Financial gravity asset management-5.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026190-48.37%32,544,367-68.44%220.45%93-51.05%50-54.55%
Dec 31, 2025250-32.98%81,888,299-17.29%561.24%124-19.48%74-43.94%
Sep 30, 2025238-35.68%62,326,392-35.80%420.97%92-50.27%94-7.84%
Jun 30, 2025376-4.08%101,484,9743.38%691.54%187-6.50%105-10.26%
Mar 31, 202539010.48%98,223,5111.40%661.50%2006.38%11620.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF8.29M5.41%1.77K
Vanguard Total Stock Mkt Idx Inv4.83M3.16%13.31K
Vanguard US Total Market Shares ETF4.36M2.78%3.80K
Vanguard Small Cap Index3.48M2.27%-6.89K
iShares Russell 2000 ETF3.42M2.23%28.81K
State Street® SPDR® S&P® Biotech ETF3.37M2.11%-33.30K
SPDR® S&P Biotech ETF2.30M1.45%5.12K
Vanguard Small Cap Growth Index Inv1.95M1.27%-1.80K
Pictet Biotech1.79M1.16%1.79M
Vanguard Institutional Extnd Mkt Idx Tr1.53M1.00%14.18K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 24, 2025Echelard Yann-Sell$162.85K
Sep 11, 2025Lonial Sagar-Sell$672.27K
Jun 13, 2025Echelard Yann-Sell$369.40K
Jan 03, 2025Power Sean A CFOSell$343.44K
Jan 06, 2025Power Sean A CFOSell$285.94K

Insider Transactions Trends

DateBuySell
2026 Q1--
2025 Q4-1
2025 Q3-1
2025 Q2-1
2025 Q1-2

TGTX Ownership FAQ

Who Owns TG Therapeutics?

TG Therapeutics shareholders are primarily institutional investors at 22.55%, followed by 7.47% insiders and 69.98% retail investors. The average institutional ownership in TG Therapeutics's industry, Biotech Stocks , is 35.75%, which TG Therapeutics falls below.

Who owns the most shares of TG Therapeutics?

TG Therapeutics’s largest shareholders are Blackrock funding, inc. /de (22.25M shares, 15.42%), Vanguard group (15.84M shares, 10.89%), and Blackrock (11.39M shares, 7.79%). Together, they hold 34.10% of TG Therapeutics’s total shares outstanding.

Does Blackrock own TG Therapeutics?

Yes, BlackRock owns 7.79% of TG Therapeutics, totaling 11.39M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 202.6M$. In the last quarter, BlackRock increased its holdings by 544.84K shares, a 5.02% change.

Who is TG Therapeutics’s biggest shareholder by percentage of total assets invested?

Act capital management is TG Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.50% of its assets in 249.02K TG Therapeutics shares, valued at 8.27M$.

Who is the top mutual fund holder of TG Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of TG Therapeutics shares, with 5.41% of its total shares outstanding invested in 8.29M TG Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools